Proteogenomic Analysis

Overview
Protein quantification is performed using the Olink Signature Q100 platform, a benchtop system designed for high-throughput readout of Olink assays based on Proximity Extension Assay (PEA) technology. PEA is coupled to a microfluidic qPCR readout, enabling highly sensitive and specific detection of protein targets.
The platform supports:

• Olink Target panels (pre-designed 48- or 96-plex panels focused on specific biological pathways or disease areas)
• Olink Flex (customizable panels with 15–21 selected proteins)
• Olink Focus (fully custom panel design)

Panels are focused on specific disease areas or biological processes and  the technology combines the best of antibody- and DNA-based methodologies to provide a unique tool for protein biomarker discovery and development.

The exponential amplification properties of PCR are utilized in PEA to achieve a strong readout signal, providing assay sensitivity on par or better than traditional enzyme-linked immunosorbent assays (ELISAs).
In a proteogenomic context, Olink-derived protein profiles can be integrated with DNA sequencing, RNA-seq and Epigenomic data. This integrative approach provides deeper regulatory insights and supports biomarker discovery, patient stratification, and a better understanding of complex diseases, including cancer and cardiovascular disorders.

Workflow

1. Sample preparation (minimal input volume required)
2. PEA reaction:
   • Incubation with antibody pairs (~16–22 h)
   • Extension and pre-amplification (~2 h)
   • Detection preparation (~2–3 h)
3. Microfluidic qPCR readout using Integrated Fluidic Circuit (IFC) on Q100
4. Data processing and normalization (NPX calculation via Olink software)
5. Downstream bioinformatic

Service Options

• Targeted analysis
• Specialized panels (e.g., 48 or 96 proteins) focused on specific areas like cardiology, oncology, or neurology